Hikma has completed its acquisition of Xellia Pharmaceuticals’ U.S. finished dosage form business and related assets following clearance under applicable U.S. antitrust laws. The acquisition ...

Hikma is offering clindamycin in 5% dextrose injection, in 300mg/50ml, 600mg/50ml and 900mg/50ml doses. The product is available in a vial. Clindamycin in 5% dextrose injection is indicated for ...

Hikma Pharmaceuticals PLC HIK shares inched up 0.88% to £19.53 Monday, on what proved to be an all-around great trading session for the stock market, with the FTSE 100 Index UKX rising 0.06% to ...

IBD is a chronic inflammation of the intestine characterised by severe stomach pain and diarrhoea affecting nearly 5 million people worldwide Riyadh – Hikma Pharmaceuticals KSA, announced the ...

Aug 27 (Reuters) - Drug companies Jazz (JAZZ.O), opens new tab and Hikma (HIK.L), opens new tab must face claims that they schemed to delay a generic version of Jazz’s blockbuster narcolepsy ...

A new appointee with more than two decades of comms experience will soon take the reins of Takeda’s worldwide brand strategy. The Big Pharma has selected Anne de Schweinitz to serve as head of ...

Worldcategory Dechra, Hikma, M&S and Diploma set to join FTSE 100 August 23, 2023 Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider ...

In this article, we are going to take a look at where Takeda Pharmaceutical Company Limited (NYSE:TAK) stands against the other cheap pharmaceutical stocks. The pharmaceutical industry is one of ...

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics ...

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...